A drug shortage database for Germany is built on a legally mandated reporting framework that determines what data is available, how current it is, and where the gaps are. Understanding this framework is essential for any pharma professional who wants to turn shortage data into sourcing decisions.

Under Section 52b of the German Medicinal Products Act (Arzneimittelgesetz, AMG), pharmaceutical manufacturers and marketing authorization holders must notify the Federal Institute for Drugs and Medical Devices (BfArM) when a supply disruption affects medicinal products deemed essential for patient care. Each notification includes the affected PZN (Pharmazentralnummer), the anticipated end date, and the reason for the disruption.

BfArM publishes these notifications on its PharmNet-Bund portal, making them accessible to healthcare professionals and commercial stakeholders. As of March 2026, the portal lists 562 active shortage entries, each representing a product currently unavailable or in limited supply. For context, BfArM recorded 1,426 shortage notifications over the course of 2023 alone — nearly three times the number reported in 2021, according to Medscape’s analysis of the German supply crisis.

The ALBVVG Framework: Germany’s Response to Chronic Shortages

The Arzneimittel-Lieferengpassbekaempfungs- und Versorgungsverbesserungsgesetz (ALBVVG), enacted in July 2023, expanded BfArM’s authority to manage shortages. Key provisions include earlier reporting obligations for manufacturers, broadened powers for BfArM to coordinate with EU partners, and incentives for domestic API production. At the EU level, the EMA launched the European Shortages Monitoring Platform (ESMP) in January 2025 to improve cross-border shortage coordination. Despite these legislative and institutional efforts, the reporting system still has well-documented limitations:

• Delayed reporting: Not all manufacturers notify BfArM on time. A 2024 BfArM evaluation found that approximately 30% of shortage notifications were submitted after the disruption had already begun.
• Unreliable end dates: Expected resolution dates are frequently extended, sometimes multiple times. Shortages initially reported as lasting four weeks have persisted for over a year.
• No alternative search: The PharmNet-Bund portal tells you what is missing but not where to find it or what commercial opportunity it represents.

For professionals in pharma import/export and hospital wholesaling, the raw BfArM data is a starting point. Turning it into actionable intelligence requires cross-referencing with international drug databases, authorization registries, and pricing data.

Why Drug Shortages in Germany Create Business Opportunities

When a medicine shortage affects a product with no therapeutic alternative available in Germany, hospitals and pharmacies are legally permitted to import the product from abroad under Article 73.3 AMG. This mechanism exists to protect patient safety, but it also creates a structured market opportunity for pharmaceutical wholesalers, importers, and niche pharma companies.

A September 2025 report by the European Court of Auditors confirmed that medicine shortages across the EU have reached record levels. Between 2022 and October 2024, national authorities reported 136 critical shortages to the EMA — including essential medicines such as thrombolytics, amoxicillin, and cyanide poisoning antidotes. Germany, as Europe’s largest pharmaceutical market, is disproportionately affected: the shortage is especially acute for off-patent medicines, including antibiotics, painkillers, antidepressants, and blood pressure medications, with an estimated 3 million patients impacted each month.

Import volumes during a shortage typically underestimate actual demand. When a product is difficult to source, many prescribers switch to suboptimal alternatives or delay treatment. Once a reliable import channel is established and availability improves, demand can increase by a factor of two to three compared to the shortage-period baseline. This means the commercial value of an import opportunity often exceeds what initial shortage data suggests.

Three Opportunity Categories

• Temporary shortages with EU alternatives: Products temporarily unavailable in Germany but commercially available in France, Belgium, Spain, or other EU member states. These represent short-term import revenue. A recent example: in early 2026, the German Federal Ministry of Health introduced special import regulations to address looming supply problems with the antibiotic benzathine benzylpenicillin.
• Chronic shortages: Products with recurring or long-duration shortages where establishing a permanent import channel provides ongoing revenue. The European Court of Auditors found that Asian producers now supply 70% of the active pharmaceutical ingredients used in the EU, making these supply chain vulnerabilities structural rather than temporary.
• Permanent market exits: Products discontinued in Germany for commercial reasons but still authorized elsewhere in the EU. These create opportunities for re-registration or long-term Article 73.3 supply.

Systematic pharmaceutical supply shortage alert monitoring is the foundation of this business model. Companies that rely on anecdotal reports or manual BfArM checks will consistently miss opportunities that data-driven competitors identify weeks or months earlier.

Article 73.3 AMG: When Can You Import Unregistered Medicines?

Article 73.3 AMG is the legal provision that permits the import of medicinal products not registered in Germany under specific conditions. It is the primary regulatory pathway for addressing drug shortages through international sourcing. Three requirements must be met simultaneously:

1. No equivalent product is available in Germany. The prescribing physician must confirm that no therapeutically equivalent medicinal product with a valid German marketing authorization is available. This includes the original product, generics, and biosimilar alternatives.
2. The product is authorized in another country. The imported medicine must hold a valid marketing authorization in its country of origin. Products from EU/EEA member states are preferred, though imports from third countries are permitted in exceptional circumstances with additional documentation.
3. A valid prescription exists. A German-licensed physician must issue a prescription specifying the international nonproprietary name (INN), dosage form, and strength.

The Practical Import Process

A hospital pharmacy or community pharmacy identifies the need and places an order with a licensed pharmaceutical wholesaler. The wholesaler sources the product from an EU supplier, handles customs documentation and GDP-compliant logistics, and delivers the product to the ordering institution. The importing wholesaler must hold a wholesale distribution authorization (Grosshandelserlaubnis) under Section 52a AMG.

Prof. Dr. Ulrich Jaehde, pharmaceutical researcher at the University of Bonn, has noted: “The Article 73.3 pathway is well-defined legally, but operationally it requires real-time data on both the German shortage landscape and international product availability. Without consolidated data, the process is slow and error-prone.”

For wholesalers and importers seeking to build a systematic business around germany drug shortage import article 73, the critical advantage lies in identifying opportunities before competitors. This requires daily monitoring of shortage databases combined with cross-referencing against international product registrations.

How to Systematically Find Shortage-Driven Import Opportunities

Identifying commercially viable import opportunities from drug shortage data requires a structured, repeatable workflow. The following five-step process transforms raw shortage notifications into actionable business intelligence.

Step 1: Filter the Shortage Database for High-Value Targets

Begin by searching a comprehensive pharmaceutical shortage monitoring software platform. Filter results for products where no therapeutic alternative is available in Germany and where the product carries hospital relevance. Products meeting both criteria represent the highest-value opportunities because hospitals have the strongest mandate and the clearest regulatory pathway for Article 73.3 imports.

On pharmazie.com, the shortage database provides a dedicated “no alternative” filter and a hospital relevance filter, enabling this initial screening in seconds rather than hours.

Step 2: Cross-Reference EU Authorization Databases

For each shortage candidate, determine whether the active ingredient is still authorized and commercially available in other EU member states. Check national registries in France (ANSM), Belgium (FAMHP), Spain (AEMPS), the Netherlands (CBG-MEB), and Austria. An EU medicine availability database that consolidates data from 50 or more countries eliminates the need to query each national authority individually.

Step 3: Check the Discontinued Products Archive

Products that have been formally discontinued in Germany, rather than temporarily unavailable, represent longer-term opportunities. Review the archive of withdrawn or discontinued marketing authorizations. If a product was discontinued for commercial reasons rather than safety concerns, it may be viable for reimport or re-registration. Historical shortage data helps distinguish between temporary supply disruptions and permanent market exits.

Step 4: Evaluate via ATC Code Hierarchy

Use the Anatomical Therapeutic Chemical (ATC) classification to identify all products sharing the same active ingredient at the fifth ATC level. This reveals potential alternatives not visible in a simple product-name search, including combination products, different salt forms, or formulations authorized under different brand names in other markets.

Step 5: Search Global Brand Name Databases via API

Extend the search beyond Europe using an API-accessible database of worldwide brand names. The same active ingredient may be marketed under dozens of different trade names globally. An API integration allows automated matching of shortage products against international registrations, enabling bulk screening rather than manual, one-product-at-a-time research.

The pharmazie.com platform provides Iceberg Search across 25+ databases, including international trade name registries covering 50+ countries. This cross-border sourcing workflow moves you from “product X is in shortage” to “product X is available in France, Belgium, and Spain under these brand names” in a single search operation.

Case Study: Discontinued Niche Products as Business Opportunities

A cardiovascular emergency medicine, formulated as an oral oil solution, was discontinued in Germany after its contract manufacturer shifted focus to veterinary pharmaceutical production. The product had generated approximately EUR 6 million in annual turnover in the German market. As of early 2026, no registered replacement product exists in Germany.

The opportunity became visible through a combination of two data sources:

• BfArM shortage notification: The initial supply disruption was flagged. When the expected end date was extended repeatedly and the marketing authorization was formally withdrawn, the status changed from “temporary shortage” to “permanent market gap.”
• International product database: A cross-reference confirmed that the same active ingredient remained authorized and commercially available in at least three other EU member states under different brand names.

For a niche pharma company evaluating this opportunity, the regulatory pathway is well defined. The active ingredient has decades of clinical use, making it eligible for a well-established use application under Article 10a of Directive 2001/83/EC. This pathway requires bibliographic evidence of efficacy and safety rather than new clinical trials, significantly reducing both cost and time to market. In the interim, the product can be supplied under Article 73.3 AMG to hospitals and pharmacies that need it.

This case illustrates a repeatable pattern. Drug shortage monitoring combined with international authorization data and discontinued product archives creates a systematic pipeline for identifying niche medicine shortage import opportunities. Companies that monitor these data sources daily maintain a structural advantage in a fragmented but commercially significant market segment.

Tools and Data Sources for Medicine Shortage Monitoring in Europe

Several data sources provide medicine shortage monitoring europe capabilities for the German market. They differ substantially in update frequency, scope of alternative-product search, and international data coverage. The following comparison reflects commercially available tools as of Q2 2026.

The BfArM portal is the authoritative primary source but offers no tools for finding alternatives or filtering by clinical relevance. The EMA’s European Shortages Monitoring Platform (ESMP), launched in January 2025, aggregates notifications from national agencies but lacks product-level sourcing capabilities. IQVIA and INSIGHT Health provide market analytics that can contextualize shortages but are not designed as operational sourcing tools. Lauer-Taxe covers German product data comprehensively but lacks the international authorization data needed for import sourcing.

The pharmazie.com platform consolidates BfArM shortage notifications with the ABDA-Artikelstamm (the authoritative German drug product database), international product registries covering 50+ countries, and ATC-based alternative matching. Its Iceberg Search feature enables parallel queries across 25+ databases from a single search, making it possible to move from “product X is in shortage” to “product X is available in three EU countries under these brand names” in one workflow step. Full REST API access enables automated monitoring and integration into existing ERP and procurement systems.

Frequently Asked Questions

What is a drug shortage database and how does it work in Germany?

A drug shortage database is a structured repository of pharmaceutical supply disruption notifications. In Germany, the system is governed by Section 52b AMG, which requires manufacturers to report shortages of essential medicines to BfArM. The data is published on the PharmNet-Bund portal. Commercial platforms like pharmazie.com enhance this raw data by adding daily updates, PZN-level mapping via the ABDA-Artikelstamm, hospital relevance filters, and cross-references to products authorized in 50+ countries.

How can I find EU alternatives for a medicine in shortage in Germany?

The most efficient method is to use a consolidated EU medicine availability database. On pharmazie.com, the Iceberg Search cross-references a product in shortage against registrations in 50+ countries, returning matching products by active ingredient, ATC code, or brand name. Without a consolidated tool, you would need to search national databases individually (ANSM in France, FAMHP in Belgium, AEMPS in Spain), which is time-consuming and prone to gaps.

What are the legal requirements for importing medicines under Article 73.3 AMG?

Three conditions must be met simultaneously: (1) no therapeutically equivalent product is available in Germany, confirmed by the prescribing physician; (2) the product holds a valid marketing authorization in its country of origin, preferably an EU/EEA member state; and (3) a valid prescription from a German-licensed physician exists. The importing wholesaler must also hold a wholesale distribution authorization under Section 52a AMG.

How does pharmazie.com differ from BfArM’s free shortage portal?

BfArM’s PharmNet-Bund portal is the official primary source but only lists what is unavailable. It provides no alternative search, no international data, no hospital relevance filter, and no API. The pharmazie.com platform adds daily-updated shortage monitoring, a “no alternative” filter, EU/international product matching across 50+ countries via Iceberg Search, PZN-level mapping through the ABDA-Artikelstamm, a discontinued products archive, and full REST API access for automated integration into ERP and procurement systems.

Can pharmaceutical shortage monitoring software predict future shortages?

Pharmaceutical shortage monitoring software cannot predict shortages with certainty, but historical data analysis reveals patterns. Products with recurring shortages, single-source active ingredients, and concentrated manufacturing in specific regions are statistically more likely to experience future disruptions. On pharmazie.com, historical shortage records and trend data support strategic decisions about whether to invest in long-term import arrangements, build safety stock, or pursue a formal marketing authorization for the German market.